文献速递认知障碍与痴呆

淀粉样蛋白阳性且5年后Tau PET仍正常个体的特征:一项ADNI研究

Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study.
PubMed 文献 · Neurology · 2022-03-21

研究基于ADNI中flortaucipir tau PET数据,定义淀粉样蛋白阳性后5年以上tau PET仍正常者为ALT组,5年内tau PET异常者为生物标志物AD组,采用病例对照设计比较两组特征。结果ALT组APOE ε4比例更低、Aβ Centiloid更低、海马体积更大、认知更保留、痴呆风险更低;Centiloid值50以80%灵敏度和特异度区分两组。

要点

  • 淀粉样蛋白阳性个体可至少5年保持tau阴性。
  • APOE ε4、较高Aβ Centiloid和海马萎缩独立与5年内tau异常风险增加相关。
  • Centiloid值50以80%灵敏度和特异度区分生物标志物AD与ALT。

核心结论

  • 淀粉样蛋白阳性个体可至少5年保持tau阴性,基线特征有助于识别痴呆风险较低的ALT个体。
  • 作者认为临床试验应采用保守的Aβ cutpoint以更好捕捉生物标志物AD高风险个体。

研究设计与样本

  • 病例对照设计,使用ADNI中所有接受flortaucipir PET参与者的数据。
  • tau PET阳性采用高斯混合模型定义,基于7个颞叶和内侧顶叶区域的对数变换标准摄取值比值,后验概率低于1%判为正常。
  • Aβ PET阳性基于ADNI cutpoint定义,识别45例ALT个体和157例生物标志物AD个体。
  • 采用logistic回归模型分析生物标志物AD vs ALT的比值比,校正性别、年龄、APOE ε4携带、Aβ Centiloid和海马体积。

主要发现

  • ALT组较生物标志物AD组APOE ε4携带者比例更低、Aβ Centiloid更低、海马体积更大、认知更保留,且更少发展为痴呆。
  • APOE ε4、较高Aβ Centiloid和海马萎缩独立与5年内tau异常风险增加相关。
  • Centiloid值50区分生物标志物AD与ALT的灵敏度和特异度均为80%。
  • 大多数ALT参与者在整个5年期间未发展为痴呆。

关键数值与推荐

  • tau PET正常定义为后验概率低于1%。
  • Aβ PET阳性基于ADNI cutpoint。
  • Centiloid值50以80%灵敏度和80%特异度区分生物标志物AD与ALT。

临床怎么用

  • 作者认为临床试验应采用保守的Aβ cutpoint以更好捕捉生物标志物AD高风险个体。
  • 基线特征可帮助识别tau阴性且痴呆风险较低的ALT个体。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Individuals with biomarker evidence of β-amyloid (Aβ) deposition are increasingly being enrolled in clinical treatment trials but there is a need to identify markers to predict which of these individuals will also develop tau deposition. We aimed to determine whether Aβ-positive individuals can remain tau-negative for at least 5 years and identify characteristics that could distinguish between these individuals and those who develop high tau within this period. METHODS: Tau PET positivity was defined using a Gaussian mixture model with log-transformed standard uptake value ratio values from 7 temporal and medial parietal regions using all participants in the Alzheimer's Disease Neuroimaging Initiative (ADNI) with flortaucipir PET. Tau PET scans were classified as normal if the posterior probability of elevated tau was less than 1%. Aβ PET positivity was defined based on ADNI cutpoints. We identified all Aβ-positive individuals from ADNI who had normal tau PET more than 5 years after their first abnormal Aβ PET (amyloid with low tau [ALT] group) and all Aβ-positive individuals with abnormal tau PET within 5 years (biomarker AD). In a case-control design, logistic regression was used to model the odds of biomarker AD vs ALT accounting for sex, age, APOE ε4 carriership, Aβ Centiloid, and hippocampal volume. RESULTS: We identified 45 individuals meeting criteria for ALT and 157 meeting criteria for biomarker AD. The ALT group had a lower proportion of APOE ε4 carriers, lower Aβ Centiloid, larger hippocampal volumes, and more preserved cognition, and were less likely to develop dementia, than the biomarker AD group. APOE ε4, higher Aβ Centiloid, and hippocampal atrophy were independently associated with increased odds of abnormal tau within 5 years. A Centiloid value of 50 effectively discriminated biomarker AD and ALT with 80% sensitivity and specificity. The majority of the ALT participants did not develop dementia throughout the 5-year interval. DISCUSSION: Aβ-positive individuals can remain tau-negative for at least 5 years. Baseline characteristics can help identify these ALT individuals who are less likely to develop dementia. Conservative Aβ cutpoints should be utilized for clinical trials to better capture individuals with high risk of developing biomarker AD.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Josephs KA, Weigand SD, Whitwell JL, et al. Characterizing Amyloid-Positive Individuals With Normal Tau PET Levels After 5 Years: An ADNI Study. Neurology. 2022. PMID: 35314506. doi:10.1212/WNL.0000000000200287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。